Radium-223 in mCRPC

Radium-223 Chloride (Alpharadin) in Patients with Bone Metastases and Castration-resistant Prostate Cancer (CRPC): A New Treatment Paradigm

Professor Sartor discusses a study of CRPC patients with bone metastases which showed that radium-223 significantly prolonged overall survival and time to first skeletal-related event, and was well tolerated.

A. Oliver Sartor, MD
Laborde Professor of Cancer Research
Departments of Medicine and Urology
Medical Director of Tulane Cancer Center
Tulane School of Medicine
New Orleans, Louisiana


E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe